ELTX

Elicio Therapeutics is a clinical-stage biotech company developing product candidates, including ELI-002 7P, aimed at addressing unmet needs in oncology and other disease areas using its platform technology. The firm is advancing its lead candidate through clinical trials with the goal of obtaining FDA approval, though it faces typical biotech risks including the need for additional funding and demonstration of safety and efficacy in human studies. Elicio remains dependent on successful trial outcomes and regulatory approvals to progress its pipeline and ultimately commercialize treatments.

Pipeline

Catalyst Calendar